Breaking News

GSK is Paying $5.1B for Cancer Drug Maker Tesaro

Adds ovarian cancer drug Zejula to its portfolio

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline (GSK) is set to acquire Tesaro, an oncology-focused company based in Waltham, MA, for roughly $5.1 billion. The deal significantly strengthens GSK’s pharmaceutical business, accelerating the build of its pipeline and commercial capability in oncology.   Tesaro is a commercial-stage biopharmaceutical company, with a major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for use in ovarian cancer. PARP inhibitors are tra...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters